The role of testosterone in colorectal carcinoma: Pathomechanisms and open questions

EPMA Journal

Volumn 7, Issue 1, 2016, Pages

  Roshan, Mohsin H K ^a   Tambo, Amos ^a   Pace, Nikolai P ^a  

^a UNIVERSITY OF MALTA   (Malta)

Author keywords

Androgen receptor repeats; Androgens; Biomarker; Colorectal cancer; Estrogen receptors; Risk prediction; Sertoli cells; Testosterone

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CASPASE 3; PROTEIN KINASE B; TESTOSTERONE;

CAG REPEAT; CANCER CELL LINE; CELL MOTILITY; COLORECTAL CARCINOMA; DISEASE ASSOCIATION; ENZYME ACTIVATION; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; REVIEW; SERTOLI CELL; SURVIVAL TIME; TESTOSTERONE BLOOD LEVEL; TUMOR PROMOTION;

EID: 84994885014     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1186/s13167-016-0071-5     Document Type: Review

References (75)

1. Statistics, SEER Cancer. "Surveillance, Epidemiology, and End Results Program." Cancer of the Colon and Rectum. National Cancer Institute. 03 Nov 2015. Web. 01 July 2016.
2. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87(2):159-70.
3. Jubb AM, Bell SM, Quirke P. Methylation and colorectal cancer. J Pathol. 2001;195(1):111-34.
4. Gryfe R, Gallinger S. Microsatellite instability, mismatch repair deficiency, and colorectal cancer. Surgery. 2001;130(1):17-20.
5. Kim YI. Folate: a magic bullet or a double edged sword for colorectal cancer prevention? Gut. 2006;55(10):1387-9.
6. Qin T, Du M, Du H, Shu Y, Wang M, Zhu L. Folic acid supplements and colorectal cancer risk: meta-analysis of randomized controlled trials. Sci Rep. 2015;5:12044.
7. Richman S, Adlard J. Left and right sided large bowel cancer: have significant genetic differences in addition to well known clinical differences. BMJ Br Med J. 2002;324(7343):931-2.
8. Lee H-K, Lee JK, Cho B. The role of androgen in the adipose tissue of males. World J Men's Health. 2013;31(2):136-40.
9. Valenti S, Cuttica CM, Fazzuoli L, Giordano G, Giusti M. Biphasic effect of nitric oxide on testosterone and cyclic GMP production by purified rat Leydig cells cultured in vitro. Int J Androl. 1999;22(5):336-41.
10. Ducsay CA, Myers DA. eNOS activation and NO function: differential control of steroidogenesis by nitric oxide and its adaptation with hypoxia. J Endocrinol. 2011;210(3):259-69.
11. Wittert G. The relationship between sleep disorders and testosterone in men. Asian J Androl. 2014;16(2):262-5.
12. Zhang L, Chang YH, Barker JL, Hu Q, Maric D, Li BS, et al. Testosterone and estrogen affect neuronal differentiation but not proliferation in early embryonic cortex of the rat: the possible roles of androgen and estrogen receptors. Neurosci Lett. 2000;281(1):57-60.
13. Takizawa S, Horii I. Endocrinological assessment of toxic effects on the male reproductive system in rats treated with 5-fluorouracil for 2 or 4 weeks. J Toxicol Sci. 2002;27(1):49-56.
14. Oskui PM, French WJ, Herring MJ, Mayeda GS, Burstein S, Kloner RA. Testosterone and the cardiovascular system: a comprehensive review of the clinical literature. J Am Heart Assoc. 2013;2(6):e000272.
15. Tambo A, Roshan MHK, Pace NP. Testosterone and cardiovascular disease. Open Cardiovasc Med J. 2016;10:1-10.
16. Al-Khazaali A, Arora R, Muttar S. Controversial effects of exogenous testosterone on cardiovascular diseases. Am J Ther. 2015. doi: 10.1097/MJT.0000000000000212.
17. Amos-Landgraf JM, Heijmans J, Wielenga MCB, Dunkin E, Krentz KJ, Clipson L, et al. Sex disparity in colonic adenomagenesis involves promotion by male hormones, not protection by female hormones. Proc Natl Acad Sci U S A. 2014;111(46):16514-9.
18. Wang R-S, Yeh S, Tzeng C-R, Chang C. Androgen receptor roles in spermatogenesis and fertility: lessons from testicular cell-specific androgen receptor knockout mice. Endocr Rev. 2009;30(2):119-32.
19. Walker WH. Non-classical actions of testosterone and spermatogenesis. Philos Trans R Soc, B. 2010;365(1546):1557-69.
20. Loss ES, Jacobsen M, Costa ZS, Jacobus AP, Borelli F, Wassermann GF. Testosterone modulates K(+)ATP channels in Sertoli cell membrane via the PLC-PIP2 pathway. Horm Metab Res. 2004;36(8):519-25.
21. Scobey M, Bertera S, Somers J, Watkins S, Zeleznik A, Walker W. Delivery of a cyclic adenosine 3',5'-monophosphate response element-binding protein (creb) mutant to seminiferous tubules results in impaired spermatogenesis. Endocrinology. 2001;142(2):948-54.
22. Walker WH, Fucci L, Habener JF. Expression of the gene encoding transcription factor cyclic adenosine 3',5'-monophosphate (cAMP) response element-binding protein (CREB): regulation by follicle-stimulating hormone-induced cAMP signaling in primary rat Sertoli cells. Endocrinology. 1995;136(8):3534-45.
23. Mruk DD, Cheng CY. Sertoli-Sertoli and Sertoli-germ cell interactions and their significance in germ cell movement in the seminiferous epithelium during spermatogenesis. Endocr Rev. 2004;25(5):747-806.
24. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2016;2015:310912.
25. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30.
26. Heyer J, Yang K, Lipkin M, Edelmann W, Kucherlapati R. Mouse models for colorectal cancer. Oncogene. 1999;18(38):5325-33.
27. Shibata H, Toyama K, Shioya H, Ito M, Hirota M, Hasegawa S, et al. Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science. 1997;278(5335):120-3.
28. Silverman KA, Koratkar R, Siracusa LD, Buchberg AM. Identification of the modifier of Min 2 (Mom2) locus, a new mutation that influences Apc-induced intestinal neoplasia. Genome Res. 2002;12(1):88-97.
29. Moon RC, Fricks CM. Influence of gonadal hormones and age on 1,2-dimethylhydrazine-induced colon carcinogenesis. Cancer. 1977;40(5 Suppl):2502-8.
30. Giroux V, Lemay F, Bernatchez G, Robitaille Y, Carrier JC. Estrogen receptor beta deficiency enhances small intestinal tumorigenesis in ApcMin/+ mice. Int J Cancer. 2008;123(2):303-11.
31. Weyant MJ, Carothers AM, Mahmoud NN, Bradlow HL, Remotti H, Bilinski RT, et al. Reciprocal expression of ERalpha and ERbeta is associated with estrogen-mediated modulation of intestinal tumorigenesis. Cancer Res. 2001;61(6):2547-51.
32. Izbicki JR, Wambach G, Hamilton SR, Harnisch E, Hogenschurz R, Izbicki W, et al. Androgen receptors in experimentally induced colon carcinogenesis. J Cancer Res Clin Oncol. 1986;112(1):39-46.
33. Rinella ES, Threadgill DW. Efficacy of EGFR inhibition is modulated by model, sex, genetic background and diet: implications for preclinical cancer prevention and therapy trials. PLoS One. 2012;7(6):e39552.
34. Anagnostopoulou V, Pediaditakis I, Alkahtani S, Alarifi SA, Schmidt EM, Lang F, et al. Differential effects of dehydroepiandrosterone and testosterone in prostate and colon cancer cell apoptosis: the role of nerve growth factor (NGF) receptors. Endocrinology. 2013;154(7):2446-56.
35. Slattery ML, Sweeney C, Murtaugh M, Ma KN, Wolff RK, Potter JD, et al. Associations between ERalpha, ERbeta, and AR genotypes and colon and rectal cancer. Cancer Epidemiol Biomark Prev. 2005;14(12):2936-42.
36. Catalano MG, Pfeffer U, Raineri M, Ferro P, Curto A, Capuzzi P, et al. Altered expression of androgen-receptor isoforms in human colon-cancer tissues. Int J Cancer. 2000;86(3):325-30.
37. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25(2):276-308.
38. Gu S, Papadopoulou N, Nasir O, Föller M, Alevizopoulos K, Lang F, et al. Activation of membrane androgen receptors in colon cancer inhibits the prosurvival signals Akt/Bad in vitro and in vivo and blocks migration via vinculin/actin signaling. Mol Med. 2011;17(1-2):48-58.
39. Gu S, Papadopoulou N, Gehring E-M, Nasir O, Dimas K, Bhavsar SK, et al. Functional membrane androgen receptors in colon tumors trigger pro-apoptotic responses in vitro and reduce drastically tumor incidence in vivo. Mol Cancer. 2009;8:114.
40. Holgren C, Dougherty U, Edwin F, Cerasi D, Taylor I, Fichera A, et al. Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas. Oncogene. 2010;29(38):5241-53.
41. Huynh N, Liu KH, Baldwin GS, He H. P21-activated kinase 1 stimulates colon cancer cell growth and migration/invasion via ERK- and AKT-dependent pathways. Biochim Biophys Acta. 2010;1803(9):1106-13.
42. Yoshioka T, Nishikawa Y, Ito R, Kawamata M, Doi Y, Yamamoto Y, et al. Significance of integrin alphavbeta5 and erbB3 in enhanced cell migration and liver metastasis of colon carcinomas stimulated by hepatocyte-derived heregulin. Cancer Sci. 2010;101(9):2011-8.
43. Huang R, Wang G, Song Y, Wang F, Zhu B, Tang Q, et al. Polymorphic CAG repeat and protein expression of androgen receptor gene in colorectal cancer. Mol Cancer Ther. 2015;14(4):1066-74.
44. Rudolph A, Shi H, Försti A, Hoffmeister M, Sainz J, Jansen L, et al. Repeat polymorphisms in ESR2 and AR and colorectal cancer risk and prognosis: results from a German population-based case-control study. BMC Cancer. 2014;14:817.
45. Honma N, Arai T, Takubo K, Younes M, Tanaka N, Mieno MN, et al. Oestrogen receptor-beta CA repeat polymorphism is associated with incidence of colorectal cancer among females. Histopathology. 2011;59(2):216-24.
46. Chen D, Ma H, Hong H, Koh SS, Huang SM, Schurter BT, et al. Regulation of transcription by a protein methyltransferase. Science. 1999;284(5423):2174-7.
47. Teyssier C, Ou CY, Khetchoumian K, Losson R, Stallcup MR. Transcriptional intermediary factor 1alpha mediates physical interaction and functional synergy between the coactivator-associated arginine methyltransferase 1 and glucocorticoid receptor-interacting protein 1 nuclear receptor coactivators. Mol Endocrinol. 2006;20(6):1276-86.
48. El Messaoudi S, Fabbrizio E, Rodriguez C, Chuchana P, Fauquier L, Cheng D, et al. Coactivator-associated arginine methyltransferase 1 (CARM1) is a positive regulator of the Cyclin E1 gene. Proc Natl Acad Sci U S A. 2006;103(36):13351-6.
49. Koh SS, Li H, Lee YH, Widelitz RB, Chuong CM, Stallcup MR. Synergistic coactivator function by coactivator-associated arginine methyltransferase (CARM) 1 and beta-catenin with two different classes of DNA-binding transcriptional activators. J Biol Chem. 2002;277(29):26031-5.
50. Kim Y-R, Lee BK, Park R-Y, Nguyen NTX, Bae JA, Kwon DD, et al. Differential CARM1 expression in prostate and colorectal cancers. BMC Cancer. 2010;10:197.
51. Barzi A, Lenz AM, Labonte MJ, Lenz H-J. Molecular pathways: estrogen pathway in colorectal cancer. Am Assoc Cancer Res. 2013;19(21):5842-8.
52. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004;350(10):991-1004.
53. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-12.
54. Castiglione F, Taddei A, Rossi Degl'Innocenti D, Buccoliero AM, Bechi P, Garbini F, et al. Expression of estrogen receptor beta in colon cancer progression. Diagn Mol Pathol. 2008;17(4):231-6.
55. Waliszewski P, Blaszczyk M, Wolinska-Witort E, Drews M, Snochowski M, Hurst RE. Molecular study of sex steroid receptor gene expression in human colon and in colorectal carcinomas. J Surg Oncol. 1997;64(1):3-11.
56. Caiazza F, Ryan EJ, Doherty G, Winter DC, Sheahan K. Estrogen receptors and their implications in colorectal carcinogenesis. Front Oncol. 2015;5:19.
57. Hartman J, Gustafsson JA. Estrogen receptors in colorectal cancer: goalkeepers, strikers, or bystanders? Cancer Prev Res (Phila). 2010;3(8):897-9.
58. Schoenfeld P, Cash B, Flood A, Dobhan R, Eastone J, Coyle W, et al. Colonoscopic screening of average-risk women for colorectal neoplasia. N Engl J Med. 2005;352(20):2061-8.
59. Gillessen S, Templeton A, Marra G, Kuo YF, Valtorta E, Shahinian VB. Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer. J Natl Cancer Inst. 2010;102(23):1760-70.
60. Lin JH, Giovannucci E. Sex hormones and colorectal cancer: what have we learned so far? J Natl Cancer Inst. 2010;102(23):1746-7.
61. Orsted DD, Nordestgaard BG, Bojesen SE. Plasma testosterone in the general population, cancer prognosis and cancer risk: a prospective cohort study. Ann Oncol. 2014;25(3):712-8.
62. Cohen PG. Aromatase, adiposity, aging and disease. The hypogonadal-metabolic-atherogenic-disease and aging connection. Med Hypotheses. 2001;56(6):702-8.
63. Lin JH, Zhang SM, Rexrode KM, Manson JE, Chan AT, Wu K, et al. Association between sex hormones and colorectal cancer risk in men and women. Clin Gastroenterol Hepatol. 2013;11(4):419-24. e1.
64. Gould DC, Petty R. The male menopause: does it exist?: for some men need investigation and testosterone treatment. West J Med. 2000;173(2):76-8.
65. Holland M, Rotenberg R, Gomez N, Marantz M, D'Angelo N. Serum testosterone: a possible marker for colorectal cancer. Medicina (B Aires). 1993;53(2):117-23.
66. Basu A, Seth S, Chauhan AK, Bansal N, Arora K, Mahaur A. Comparative study of tumor markers in patients with colorectal carcinoma before and after chemotherapy. Ann Trans Med. 2016;4(4):71.
67. Micheli A, Meneghini E, Secreto G, Berrino F, Venturelli E, Cavalleri A, et al. Plasma testosterone and prognosis of postmenopausal breast cancer patients. J Clin Oncol. 2007;25(19):2685-90.
68. Grech G, Zhan X, Yoo BC, Bubnov R, Hagan S, Danesi R, et al. EPMA position paper in cancer: current overview and future perspectives. EPMA J. 2015;6(1):9.
69. Gonzalez-Pons M, Cruz-Correa M. Colorectal cancer biomarkers: where are we now? Biomed Res Int. 2015;2015:14.
70. Herold DA, Fitzgerald RL. Immunoassays for testosterone in women: better than a guess? Clin Chem. 2003;49(8):1250-1.
71. Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab. 2004;89(2):534-43.
72. Moal V, Mathieu E, Reynier P, Malthiery Y, Gallois Y. Low serum testosterone assayed by liquid chromatography-tandem mass spectrometry. Comparison with five immunoassay techniques. Clin Chim Acta Int J Clin Chem. 2007;386(1-2):12-9.
73. Golubnitschaja O, Costigliola V, EPMA. General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J. 2012;3(1):14.
74. Drucker E, Krapfenbauer K. Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine. EPMA J. 2013;4(1):7.
75. Yu M, Grady WM. Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer. Ther Adv Gastroenterol. 2012;5(5):319-37.